

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



邁博藥業
Mabpharm Limited
迈博药业有限公司

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2181)

**POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING
HELD ON FRIDAY, APRIL 30, 2021**

References are made to the Notice (the “**Notice**”) of the extraordinary general meeting (the “**EGM**”) and the circular (the “**Circular**”) of Mabpharm Limited (the “**Company**”) both dated April 13, 2021. Unless otherwise defined, capitalised terms used herein shall have the same meanings as those defined in the Circular.

POLL RESULTS

At the EGM of the Company held on Friday, April 30, 2021, all the proposed resolutions (the “**Resolutions**”) as set out in the Notice were duly passed by the Independent Shareholders as ordinary resolutions by way of poll.

As at the date of the EGM, the total number of issued Shares was 4,124,080,000. Mr. Guo Jianjun, one of the non-executive Directors and controlling shareholders of the Company, and Ms. Guo Hua (an associate of Mr. Guo Jianjun) indirectly controls 5% and 61.67% of the voting rights in Sinomab respectively. Biomabs is a wholly-owned subsidiary of Sinomab. Therefore, Mr. Guo Jianjun who is interested in 2,227,000,000 Shares indirectly through Asia Mabtech Limited and United Circuit Limited (representing approximately 54% of all issued Shares) as at the date of the EGM, was required under the Listing Rules to abstain and had abstained, from voting on the Resolutions at the EGM. Save as disclosed above, to the best of the Directors’ knowledge, information and belief, having made all reasonable enquiry, no other Shareholder was required under the Listing Rules to abstain from voting on the Resolutions at the EGM. Accordingly, the total number of Shares entitling the respective holders to attend and vote on the resolutions at the EGM was 1,897,080,000 Shares (representing approximately 46% of the total issued Shares). There were no Shares entitling the Shareholders to attend and abstain from voting in favour at the EGM as set out in Rule 13.40 of the Listing Rules. Save as disclosed above, none of the Shareholders have indicated in the Circular that they intended to vote against or to abstain from voting on any Resolutions at the EGM.

The Company's branch share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, was appointed as the scrutineer at the EGM for the purpose of vote-taking. The Board of the Company is pleased to announce the poll results in respect of the Resolutions proposed at the EGM as follows:

Ordinary Resolutions		Number of Votes (%)	
		For	Against
1.	<p>(a) To approve, ratify and confirm the entering into of the license agreement in respect of CMAB807 (the "License Agreement") dated March 1, 2021 entered into between Taizhou Mabtech Pharmaceutical Limited* (泰州邁博太科藥業有限公司) ("Taizhou Pharmaceutical"), an indirect wholly-owned subsidiary of Mabpharm Limited (the "Company") and Shanghai Biomabs Pharmaceuticals Co., Ltd.* (上海百邁博製藥有限公司) ("Biomabs") and the transaction contemplated thereunder; and</p> <p>(b) To authorize the director(s) of the Company, for and on behalf of the Company to, amongst other matters, sign, execute and deliver or to authorize the signing, execution and delivery of all such documents and to do all such things as they may in their absolute discretion consider necessary, expedient or desirable to implement and/or to give effect to or otherwise in connection with the License Agreement.</p>	1,533,101,500 (100%)	0 (0%)
2.	<p>(a) To approve, ratify and confirm the entering into of the clinical trials agreement in respect of CMAB807 (the "Clinical Trials Agreement") dated March 1, 2021 entered into between Taizhou Pharmaceutical, and Biomabs and the transactions contemplated thereunder;</p> <p>(b) To approve the proposed annual cap amounts for the maximum aggregated agreed reimbursement payable under the Clinical Trials Agreement for the three years ending 31 December 2023 as set out in the Circular; and</p> <p>(c) To authorize the director(s) of the Company, for and on behalf of the Company to, amongst other matters, sign, execute and deliver or to authorize the signing, execution and delivery of all such documents and to do all such things as they may in their absolute discretion consider necessary, expedient or desirable to implement and/or to give effect to or otherwise in connection with the Clinical Trials Agreement.</p>	1,533,101,500 (100%)	0 (0%)

Ordinary Resolutions		Number of Votes (%)	
		For	Against
3	<p>(a) To approve, ratify and confirm the entering into of the contract development and manufacturing agreement in respect of CMAB807 (the “CDMO Agreement”) dated March 1, 2021 entered into between Taizhou Pharmaceutical and Biomabs and the transactions contemplated thereunder;</p> <p>(b) To approve the proposed annual cap amounts for the fees payable under the CDMO Agreement for the three years ending 31 December 2023 as set out in the Circular; and</p> <p>(c) To authorize the director(s) of the Company, for and on behalf of the Company to, amongst other matters, sign, execute and deliver or to authorize the signing, execution and delivery of all such documents and to do all such things as they may in their absolute discretion consider necessary, expedient or desirable to implement and/or to give effect to or otherwise in connection with the CDMO Agreement.</p>	1,533,101,500 (100%)	0 (0%)

* For identification purpose only

As more than 50% of the votes were cast in favour of each of the above ordinary resolutions numbered 1 to 3, all of the above resolutions were duly passed by the Independent Shareholders as ordinary resolutions of the Company at the EGM.

By order of the Board
Mabpharm Limited
Jiao Shuge
Chairman

Shanghai, the PRC, April 30, 2021

As at the date of this announcement, the Board of Directors comprises Dr. Wang Hao, Mr. Tao Jing, Mr. Li Yunfeng, and Dr. Li Jing as executive Directors; Mr. Jiao Shuge and Mr. Guo Jianjun as non-executive Directors; and Mr. Guo Liangzhong, Dr. Zhang Yanyun and Dr. Liu Linqing as independent non-executive Directors.